Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Diabetes Drug Safety Might Be Best Assessed With Real-World Data

Executive Summary

Meta-analysis published in JAMA suggests registry-based studies could be alternative to large cardiovascular outcomes trials.


Related Content

Diabetes Trials Could Include Hypoglycemia As Patient-Reported Outcome
PDUFA's 'Real-World' Journey Expected To Be Slow Walk
FDA To Join The 'Real World' Under PDUFA VI
Can A Safety Study Support A Superiority Claim? Barely, FDA Advisors Say
Real-World Evidence May Find A Home On Breakthrough Pathway
FDA's Califf On Real World Evidence: 'Use It For The Right Purposes'
Will Novo’s LEADER Trial Move GLP-1 To The Front Line In High-Risk Diabetes?
Sitagliptin Shows No Increased Cardiovascular Risk In Merck’s TECOS Trial
Will CV Verdicts For Onglyza, Nesina Cause FDA To Change Its Tune On Antidiabetic Safety?
Alogliptin, Saxagliptin Show Neutral CV Effects In Outcomes Studies


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts